Trial reportMolecular imaging and biology2011
Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma.
Trial report in Molecular imaging and biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 32 citations in OpenAlex.
- A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.Journal of radiation research · 2013Trial
- Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET.Frontiers in oncology · 2021Review
- YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells.Journal of radiation research · 2020Article
- Integrating molecular nuclear imaging in clinical research to improve anticancer therapy.Nature reviews. Clinical oncology · 2019Review
- Molecular mechanisms of hypoxia in cancer.Clinical and translational imaging · 2017Review
- Imaging tumour hypoxia with positron emission tomography.British journal of cancer · 2015Review
- Positron emission tomography to assess hypoxia and perfusion in lung cancer.World journal of clinical oncology · 2014Review
- Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.European journal of nuclear medicine and molecular imaging · 2014Article
- Molecular imaging of tumor hypoxia with positron emission tomography.Radiation research · 2014Review
- Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to investigate the changes of tumor hypoxia as a result of neoadjuvant chemotherapy (NAC) by measuring the changes of [(18)F]fluoromisonidazole ([(18)F]FMISO) positron emission tomography (PET) uptake, as well as to look into the ability of [(18)F]FMISO PET to predict the NAC result. PROCEDURES: A total of 13 patients with locally advanced head and neck squamous cell carcinoma underwent [(18)F]FMISO PET scans before and after NAC. For analysis of PET index, maximum standardized uptake value, tumor-to-muscle ratio, and hypoxic volume (HV) were measured.
resultsAll PET indexes of [(18)F]FMISO significantly decreased after NAC. Although HV in primary tumor and a few indexes before NAC in responder was lower than that in nonresponder, none of the indexes were statistically significant.
conclusionsPretreatment [(18)F]FMISO could not predict NAC outcome in this study. However, [(18)F]FMISO uptake significantly decreased after NAC, and [(18)F]FMISO PET seemed to be a useful noninvasive tool for detecting hypoxia reduction after NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.